0000000000564254
AUTHOR
Sheila Harvey
Additional file 5: Table S4. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Final risk models at admission, 24Â h and end of calendar day 3. (DOC 44 kb)
Additional file 6: Figure S2. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Area under the operating curve for clinical decision rules. (DOC 110 kb)
Additional file 5: Table S4. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Final risk models at admission, 24Â h and end of calendar day 3. (DOC 44 kb)
Additional file 1: Table S1. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Site of Candida invasive fungal disease (Nâ =â 359). (DOC 31 kb)
Additional file 3: Table S2. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Therapies received, fungal colonisation, mortality and length of stay by invasive fungal disease subgroup. (DOC 61 kb)
Additional file 4: Table S3. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Description of patients included at each time point in each of the development and validation samples. (DOC 37 kb)
Additional file 4: Table S3. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Description of patients included at each time point in each of the development and validation samples. (DOC 37 kb)
Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units.
BACKGROUND: Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. METHODS: Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in t…
Additional file 3: Table S2. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Therapies received, fungal colonisation, mortality and length of stay by invasive fungal disease subgroup. (DOC 61 kb)
Additional file 2: Figure S1. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Timing of Candida invasive fungal disease relative to critical care unit admission (Nâ =â 359). (DOC 27 kb)
Additional file 6: Figure S2. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units
Area under the operating curve for clinical decision rules. (DOC 110 kb)